Developer docs
API playgroundTry for free, no card

Search company profiles

Cyrano Therapeutics

Full company profile

uuid00024zn

Namestring
Cyrano Therapeutics
Legal namestring
Cyrano Therapeutics, Inc.
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Cyrano Therapeutics, Inc. is a private, venture-backed clinical-stage regenerative medicine company headquartered in Delray Beach, Florida, founded in 2014. The company is developing CYR-064, a patent-protected intranasal soft-mist spray formulation of theophylline (a broad-spectrum phosphodiesterase inhibitor) designed to inhibit cAMP degradation and enhance olfactory neuron excitability, with the goal of restoring sense of smell in patients with persistent post-viral hyposmia. Drug delivery relies on a licensed Resyca soft-mist platform paired with an Ursatec quality pump, enabling droplet sizes small enough to reach the olfactory region at the top of the nasal cavity. The Phase 2 FLAVOR trial, a 32-week randomized, double-blind, placebo-controlled study, completed enrollment at 14 US clinical sites (151 patients) and reported positive topline results in February 2026, meeting the primary safety endpoint and key secondary efficacy endpoints with no treatment-related serious adverse events; the company plans to initiate a pivotal Phase 3 trial in the second half of 2026. CYR-064 has no FDA-approved competitor in its target indication, which spans 60+ million patients in the US, Europe, and Japan with persistent post-viral olfactory dysfunction.

Cyrano operates a clinical-stage go-to-market motion centered on multi-site Phase 2 and Phase 3 trial execution across US academic and specialty centers, with future commercialization expected to follow a traditional pharmaceutical launch model targeting otolaryngologists and primary care physicians. The company has executed two strategic partnerships in 2025 to extend its commercial footprint and supply chain: an option agreement with Kyorin Pharmaceutical (Feb 2025) granting Japan development and commercialization rights in exchange for upfront, milestone, and royalty payments, and an exclusive licensing agreement with Resyca (March 2025) for soft-mist nasal spray technology used in CYR-064. The company is also funding an investigator-initiated feasibility study in Parkinson's Disease patients, where olfactory dysfunction is an early symptom in ~95% of cases, as a potential indication expansion.

The company is pre-revenue with no commercialized product and has raised $21.8 million across two funding rounds to date, including a $12.8M Series A and a $9.0M Series B closed in January 2024 co-led by the Florida Opportunity Fund (DeepWork Capital), Lumira Ventures, and Remiges Ventures. Its leadership team includes founder and CEO Rick Geoffrion, Chief Medical Advisor Ron Kuppersmith (former President of the American Academy of Otolaryngology-Head and Neck Surgery), and CMC Senior Advisor Michael Lusty (25+ years in nasal/inhalation product development including Nasonex and Nayzilam). The board includes representatives from each institutional investor and John Kollins, former CEO of Satsuma Pharmaceuticals.

Short descriptiontext

Cyrano Therapeutics is a private clinical-stage biotech developing CYR-064, an intranasal theophylline soft-mist spray aimed at restoring smell function in patients with persistent post-viral hyposmia, with no FDA-approved competitor in its target indication of 60M+ patients across the US, Europe, and Japan.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersDelray Beach, United States
HQ citystring
Delray Beach
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
intranasal drug delivery, olfactory dysfunction therapy, phosphodiesterase inhibitors, clinical-stage biotechnology, regenerative medicine therapeutics
Industry1 code
PRIMARYHLAHAIAK
Nasal Drug Delivery Devices (Sprays/Powder Devices)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Olfactory Therapeutics
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Product Revenue
TypeOne Time License
Description

As a clinical-stage biotech company, Cyrano does not yet generate revenue. The company is developing CYR-064 as a potential first-approved therapy for post-viral smell loss. Upon regulatory approval, the company plans to commercialize the product through traditional pharmaceutical sales channels, targeting otolaryngologists and healthcare providers treating patients with hyposmia. Revenue will come from product sales following FDA approval.

cyranotherapeutics.com
2Licensing and Milestone Payments
TypeLicensing Royalties
Description

Cyrano receives upfront option fees, milestone payments tied to development and commercialization progress, and royalties based on a percentage of net sales from Kyorin Pharmaceutical for CYR-064 in Japan. This provides non-dilutive capital during development phase and ongoing royalty stream upon commercialization in Japan.

cyranotherapeutics.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Cyrano Therapeutics is developing CYR-064, a clinical-stage intranasal soft-mist spray formulation of theophylline (a broad-spectrum phosphodiesterase inhibitor) intended to restore olfactory function in patients with persistent post-viral smell loss (hyposmia). The product uses licensed Resyca soft mist nasal spray technology to deliver droplet sizes targeted to the olfactory region at the top of the nasal cavity, inhibiting cAMP degradation and enhancing olfactory neuron excitability. The therapy is currently in Phase 2 clinical development with a pivotal Phase 3 trial planned for H2 2026.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Phase 2 FLAVOR trial met primary safety and tolerability endpoint with no treatment-related serious adverse events in 151 patients
+3 more records
Product overview1 text field

Cyrano Therapeutics is developing a single-product portfolio focused on CYR-064, a proprietary intranasal regenerative therapy for persistent post-viral smell loss (hyposmia). Delivered as a soft-mist nasal spray using licensed Resyca technology, CYR-064 is a patent-protected formulation of theophylline that targets the olfactory neurons to restore smell function. The company is advancing CYR-064 through Phase 2 clinical trials, with plans for Phase 3 development.

Product and service1 record
1CYR-064
CategoryCore product - Intranasal regenerative therapeutic
Description

CYR-064 is an intranasal soft-mist spray formulation of theophylline (a broad-spectrum phosphodiesterase inhibitor) designed to inhibit cAMP degradation, increase intracellular concentrations, and enhance olfactory neuron excitability for the treatment of persistent post-viral smell loss (hyposmia). The product uses Resyca's licensed soft mist nasal spray technology with a Ursatec pump to deliver droplet sizes small enough to reach the olfactory region at the top of the nasal cavity. The Phase 2 FLAVOR trial in 151 patients met primary safety and key secondary efficacy endpoints with no treatment-related serious adverse events, supporting advancement to Phase 3 development in H2 2026.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-03-18
Description

Cyrano Therapeutics entered into an exclusive licensing agreement with Resyca on March 18, 2025 for Resyca's proprietary soft mist nasal spray technology for the treatment of chemosensory disorders including post-viral smell loss (hyposmia). CYR-064 utilizes Resyca's technology in its Phase 2 FLAVOR clinical study. The technology enables delivery of droplet sizes small enough to reach the olfactory region at the top of the nasal cavity, providing consistent drug deposition to the therapeutic target.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-02-14
Description

Kyorin Pharmaceutical entered into an option agreement with Cyrano Therapeutics on February 14, 2025 for CYR-064, a novel treatment for post-viral loss of smell (hyposmia). Kyorin obtains option for license to develop and commercialize CYR-064 in Japan. Kyorin will pay an option fee, and upon exercising the option, will provide Cyrano with upfront payment, milestone payments tied to development and commercialization progress, and royalties based on a percentage of net sales following launch.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-02-04
Description

Cyrano is providing clinical material to support an investigator-initiated feasibility study evaluating CYR-064 in Parkinson's Disease patients conducted by independent investigators. This represents exploratory research collaboration for potential future indication expansion.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers8 records
TypeDirect peer
Description

OptiNose develops and commercializes intranasal drug delivery products using its proprietary Breath Powered delivery platform, addressing ENT and CNS indications. Its focus on localized nasal delivery and demonstrated ability to develop and launch nasal therapeutics makes it a direct comparable to Cyrano's intranasal theophylline approach.

TypeDirect peer
Description

Impel NeuroPharma developed INP104 (Trudhesa), an intranasal delivery platform using Precision Olfactory Delivery that targets the upper nasal cavity for migraine. Its targeted upper-nasal-cavity delivery approach parallels CYR-064's soft-mist delivery to the olfactory region, and its transition to commercialization serves as a useful comparator for Cyrano's commercial trajectory.

TypeDirect peer
Description

Neurelis developed Nayzilam (nasal midazolam) for seizure rescue, a nasal spray therapeutic with similar regulatory, manufacturing, and commercial dynamics to CYR-064. Senior Cyrano advisor Michael Lusty previously worked on the Nayzilam development program at Ikano Therapeutics, providing direct linkage between the two companies.

TypeDirect peer
Description

Satsuma Pharmaceuticals developed STS101, an intranasal powder formulation of dihydroergotamine for acute migraine, and completed an IPO on Nasdaq prior to its acquisition. Its intranasal drug development and regulatory pathway is closely analogous to Cyrano's CYR-064 program and the company's former CEO John Kollins now serves on Cyrano's board.

TypeDirect peer
Description

Bionorica develops botanical pharmaceuticals for ENT and respiratory conditions including Sinupret for sinus and nasal disorders. Its focus on chronic nasal/respiratory therapeutics and European commercial presence provides a direct analog to Cyrano's post-viral hyposmia opportunity in adjacent ENT indications.

TypeEmerging player
Description

Auris Medical is a specialty biopharmaceutical company developing therapies for sensory organ disorders, primarily ear-related conditions such as hearing loss and vertigo. Its focus on restoring sensory function in ENT indications aligns thematically with Cyrano's work on smell restoration, though delivery technology and indication differ.

7Otonomy
TypeBroad incumbent
Description

Otonomy is a biopharmaceutical company developing therapeutics for ear disorders and balance conditions, with multiple clinical-stage nasal/otic drug delivery assets. Its pipeline of locally-delivered, sensory-disease therapeutics positions it as a broader incumbent in the sensory biotherapeutics space where Cyrano operates.

TypeBroad incumbent
Description

Acclarent, now part of Johnson & Johnson MedTech, provides ENT products including drug delivery and surgical solutions for chronic sinusitis and nasal conditions. As a large, commercially-established ENT incumbent, it represents a potential large-market acquirer or channel partner for Cyrano's olfactory therapeutics.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cyrano Therapeutics

Olfactory Therapeuticscyranotherapeutics.com

Cyrano Therapeutics is a private clinical-stage biotech developing CYR-064, an intranasal theophylline soft-mist spray aimed at restoring smell function in patients with persistent post-viral hyposmia, with no FDA-approved competitor in its target indication of 60M+ patients across the US, Europe, and Japan.

What Cyrano Therapeutics does

Cyrano Therapeutics, Inc. is a private, venture-backed clinical-stage regenerative medicine company headquartered in Delray Beach, Florida, founded in 2014. The company is developing CYR-064, a patent-protected intranasal soft-mist spray formulation of theophylline (a broad-spectrum phosphodiesterase inhibitor) designed to inhibit cAMP degradation and enhance olfactory neuron excitability, with the goal of restoring sense of smell in patients with persistent post-viral hyposmia. Drug delivery relies on a licensed Resyca soft-mist platform paired with an Ursatec quality pump, enabling droplet sizes small enough to reach the olfactory region at the top of the nasal cavity. The Phase 2 FLAVOR trial, a 32-week randomized, double-blind, placebo-controlled study, completed enrollment at 14 US clinical sites (151 patients) and reported positive topline results in February 2026, meeting the primary safety endpoint and key secondary efficacy endpoints with no treatment-related serious adverse events; the company plans to initiate a pivotal Phase 3 trial in the second half of 2026. CYR-064 has no FDA-approved competitor in its target indication, which spans 60+ million patients in the US, Europe, and Japan with persistent post-viral olfactory dysfunction.

Cyrano operates a clinical-stage go-to-market motion centered on multi-site Phase 2 and Phase 3 trial execution across US academic and specialty centers, with future commercialization expected to follow a traditional pharmaceutical launch model targeting otolaryngologists and primary care physicians. The company has executed two strategic partnerships in 2025 to extend its commercial footprint and supply chain: an option agreement with Kyorin Pharmaceutical (Feb 2025) granting Japan development and commercialization rights in exchange for upfront, milestone, and royalty payments, and an exclusive licensing agreement with Resyca (March 2025) for soft-mist nasal spray technology used in CYR-064. The company is also funding an investigator-initiated feasibility study in Parkinson's Disease patients, where olfactory dysfunction is an early symptom in ~95% of cases, as a potential indication expansion.

The company is pre-revenue with no commercialized product and has raised $21.8 million across two funding rounds to date, including a $12.8M Series A and a $9.0M Series B closed in January 2024 co-led by the Florida Opportunity Fund (DeepWork Capital), Lumira Ventures, and Remiges Ventures. Its leadership team includes founder and CEO Rick Geoffrion, Chief Medical Advisor Ron Kuppersmith (former President of the American Academy of Otolaryngology-Head and Neck Surgery), and CMC Senior Advisor Michael Lusty (25+ years in nasal/inhalation product development including Nasonex and Nayzilam). The board includes representatives from each institutional investor and John Kollins, former CEO of Satsuma Pharmaceuticals.

Cyrano Therapeutics firmographics

Firmographics
Name
Cyrano Therapeutics
Legal name
Cyrano Therapeutics, Inc.
Website
https://cyranotherapeutics.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
1–10 employees
Short description
Cyrano Therapeutics is a private clinical-stage biotech developing CYR-064, an intranasal theophylline soft-mist spray aimed at restoring smell function in patients with persistent post-viral hyposmia, with no FDA-approved competitor in its target indication of 60M+ patients across the US, Europe, and Japan.
Ownership category
akta.pro rank

Cyrano Therapeutics industry classification

Industry
Product category
Olfactory Therapeutics
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAHAIAK
Nasal Drug Delivery Devices (Sprays/Powder Devices)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)

Keywords

  • Intranasal drug delivery
  • Olfactory dysfunction therapy
  • Phosphodiesterase inhibitors
  • Clinical-stage biotechnology
  • Regenerative medicine therapeutics

Where Cyrano Therapeutics is headquartered

Location

Headquarters

HQ city
Delray Beach
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Cyrano Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Product Revenue: As a clinical-stage biotech company, Cyrano does not yet generate revenue. The company is developing CYR-064 as a potential first-approved therapy for post-viral smell loss. Upon regulatory approval, the company plans to commercialize the product through traditional pharmaceutical sales channels, targeting otolaryngologists and healthcare providers treating patients with hyposmia. Revenue will come from product sales following FDA approval.
  2. Licensing and Milestone Payments: Cyrano receives upfront option fees, milestone payments tied to development and commercialization progress, and royalties based on a percentage of net sales from Kyorin Pharmaceutical for CYR-064 in Japan. This provides non-dilutive capital during development phase and ongoing royalty stream upon commercialization in Japan.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Cyrano Therapeutics product offering

Product offering

Core offering

Cyrano Therapeutics is developing CYR-064, a clinical-stage intranasal soft-mist spray formulation of theophylline (a broad-spectrum phosphodiesterase inhibitor) intended to restore olfactory function in patients with persistent post-viral smell loss (hyposmia). The product uses licensed Resyca soft mist nasal spray technology to deliver droplet sizes targeted to the olfactory region at the top of the nasal cavity, inhibiting cAMP degradation and enhancing olfactory neuron excitability. The therapy is currently in Phase 2 clinical development with a pivotal Phase 3 trial planned for H2 2026.

Product overview

Cyrano Therapeutics is developing a single-product portfolio focused on CYR-064, a proprietary intranasal regenerative therapy for persistent post-viral smell loss (hyposmia). Delivered as a soft-mist nasal spray using licensed Resyca technology, CYR-064 is a patent-protected formulation of theophylline that targets the olfactory neurons to restore smell function. The company is advancing CYR-064 through Phase 2 clinical trials, with plans for Phase 3 development.

Differentiator

Problem solved

Functional benefit

Products and services

  • CYR-064 CYR-064 is an intranasal soft-mist spray formulation of theophylline (a broad-spectrum phosphodiesterase inhibitor) designed to inhibit cAMP degradation, increase intracellular concentrations, and enhance olfactory neuron excitability for the treatment of persistent post-viral smell loss (hyposmia). The product uses Resyca's licensed soft mist nasal spray technology with a Ursatec pump to deliver droplet sizes small enough to reach the olfactory region at the top of the nasal cavity. The Phase 2 FLAVOR trial in 151 patients met primary safety and key secondary efficacy endpoints with no treatment-related serious adverse events, supporting advancement to Phase 3 development in H2 2026.

Quantifiable outcome

  • Phase 2 FLAVOR trial met primary safety and tolerability endpoint with no treatment-related serious adverse events in 151 patients
  • +3 more outcomes

Companies that use Cyrano Therapeutics

Customer profile

Segments2 records

Ideal customer profiles2 records

Cyrano Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Cyrano Therapeutics partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • ResycacoreTechnology or Integration · 18 March 2025Cyrano Therapeutics entered into an exclusive licensing agreement with Resyca on March 18, 2025 for Resyca's proprietary soft mist nasal spray technology for the treatment of chemosensory disorders including post-viral smell loss (hyposmia). CYR-064 utilizes Resyca's technology in its Phase 2 FLAVOR clinical study. The technology enables delivery of droplet sizes small enough to reach the olfactory region at the top of the nasal cavity, providing consistent drug deposition to the therapeutic target.
  • Kyorin Pharmaceutical Co., Ltd.coreOEM/ Whitelabel/ Licensing Partner · 14 February 2025Kyorin Pharmaceutical entered into an option agreement with Cyrano Therapeutics on February 14, 2025 for CYR-064, a novel treatment for post-viral loss of smell (hyposmia). Kyorin obtains option for license to develop and commercialize CYR-064 in Japan. Kyorin will pay an option fee, and upon exercising the option, will provide Cyrano with upfront payment, milestone payments tied to development and commercialization progress, and royalties based on a percentage of net sales following launch.
  • Investigator Research SitesminorStrategic or Co-development Partner · 4 February 2025Cyrano is providing clinical material to support an investigator-initiated feasibility study evaluating CYR-064 in Parkinson's Disease patients conducted by independent investigators. This represents exploratory research collaboration for potential future indication expansion.

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

Cyrano Therapeutics competitors and assessment

Company assessment

Direct peers

  • OptiNose: OptiNose develops and commercializes intranasal drug delivery products using its proprietary Breath Powered delivery platform, addressing ENT and CNS indications. Its focus on localized nasal delivery and demonstrated ability to develop and launch nasal therapeutics makes it a direct comparable to Cyrano's intranasal theophylline approach.
  • Impel NeuroPharma: Impel NeuroPharma developed INP104 (Trudhesa), an intranasal delivery platform using Precision Olfactory Delivery that targets the upper nasal cavity for migraine. Its targeted upper-nasal-cavity delivery approach parallels CYR-064's soft-mist delivery to the olfactory region, and its transition to commercialization serves as a useful comparator for Cyrano's commercial trajectory.
  • Neurelis: Neurelis developed Nayzilam (nasal midazolam) for seizure rescue, a nasal spray therapeutic with similar regulatory, manufacturing, and commercial dynamics to CYR-064. Senior Cyrano advisor Michael Lusty previously worked on the Nayzilam development program at Ikano Therapeutics, providing direct linkage between the two companies.
  • Satsuma Pharmaceuticals: Satsuma Pharmaceuticals developed STS101, an intranasal powder formulation of dihydroergotamine for acute migraine, and completed an IPO on Nasdaq prior to its acquisition. Its intranasal drug development and regulatory pathway is closely analogous to Cyrano's CYR-064 program and the company's former CEO John Kollins now serves on Cyrano's board.
  • Bionorica: Bionorica develops botanical pharmaceuticals for ENT and respiratory conditions including Sinupret for sinus and nasal disorders. Its focus on chronic nasal/respiratory therapeutics and European commercial presence provides a direct analog to Cyrano's post-viral hyposmia opportunity in adjacent ENT indications.

Emerging players

  • Auris Medical: Auris Medical is a specialty biopharmaceutical company developing therapies for sensory organ disorders, primarily ear-related conditions such as hearing loss and vertigo. Its focus on restoring sensory function in ENT indications aligns thematically with Cyrano's work on smell restoration, though delivery technology and indication differ.

Broad incumbents

  • Otonomy: Otonomy is a biopharmaceutical company developing therapeutics for ear disorders and balance conditions, with multiple clinical-stage nasal/otic drug delivery assets. Its pipeline of locally-delivered, sensory-disease therapeutics positions it as a broader incumbent in the sensory biotherapeutics space where Cyrano operates.
  • Acclarent (Johnson & Johnson MedTech): Acclarent, now part of Johnson & Johnson MedTech, provides ENT products including drug delivery and surgical solutions for chronic sinusitis and nasal conditions. As a large, commercially-established ENT incumbent, it represents a potential large-market acquirer or channel partner for Cyrano's olfactory therapeutics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Cyrano Therapeutics social profiles

Digital presence

Cyrano Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cyrano Therapeutics leadership team

Management profile

Number of profiles

Profiles8 records

Cyrano Therapeutics funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cyrano Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cyrano Therapeutics

What does Cyrano Therapeutics do?

Cyrano Therapeutics is developing CYR-064, a clinical-stage intranasal soft-mist spray formulation of theophylline (a broad-spectrum phosphodiesterase inhibitor) intended to restore olfactory function in patients with persistent post-viral smell loss (hyposmia). The product uses licensed Resyca soft mist nasal spray technology to deliver droplet sizes targeted to the olfactory region at the top of the nasal cavity, inhibiting cAMP degradation and enhancing olfactory neuron excitability. The therapy is currently in Phase 2 clinical development with a pivotal Phase 3 trial planned for H2 2026.

Is Cyrano Therapeutics a public or private company?

Cyrano Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Cyrano Therapeutics founded?

Cyrano Therapeutics was founded in 2014. It employs 1 to 10 people.

Where is Cyrano Therapeutics based?

Cyrano Therapeutics is headquartered in Delray Beach, United States, in the North America region.

How does Cyrano Therapeutics make money?

Two revenue lines are on record. Pharmaceutical Product Revenue is the primary driver. The others are licensing and Milestone Payments.

Who are Cyrano Therapeutics's main competitors?

Direct peers on record are OptiNose, Impel NeuroPharma, Neurelis, Satsuma Pharmaceuticals and Bionorica. Auris Medical is listed as an emerging player. Broad incumbents are Otonomy and Acclarent (Johnson & Johnson MedTech).

Does Cyrano Therapeutics have an API?

No public API is recorded for Cyrano Therapeutics.

What industry is Cyrano Therapeutics in?

Cyrano Therapeutics's product category is Olfactory Therapeutics. Its primary akta.pro industry code is HLAHAIAK, Nasal Drug Delivery Devices (Sprays/Powder Devices). Its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswireCyrano’s Phase II trial of CYR-064 meets primary safety endpointCyrano Therapeutics reported that its Phase II FLAVOR trial of CYR-064 met the primary safety endpoint in patients with persistent post-viral smell loss. The placebo-controlled trial of 151 participants showed no serious adverse events and comparable overall rates. In participants under 60, high-dose CYR-064 produced statistically significant gains in smell function over 24 weeks, and the company plans to advance to Phase III.FierceBiotechCyrano noses toward pivotal trial after midphase smell loss winCyrano Therapeutics announced positive results from its phase 2 Flavor study, meeting the primary safety and tolerability endpoint for CYR-064, an intranasal theophylline formulation being developed for persistent post-viral smell loss (hyposmia). The trial enrolled 151 patients and showed no treatment-related serious adverse events, with durable improvements across secondary efficacy endpoints; the company plans to share detailed data at a medical conference and initiate a phase 3 trial in the second half of 2024. Cyrano has raised $21.8 million across two funding rounds and granted Kyorin Pharmaceutical an option to license CYR-064 in Japan, positioning the treatment as a potential first approved therapy for the condition affecting millions.PR NewswireCyrano Therapeutics Announces Positive Topline Results from Phase 2 FLAVOR Trial of CYR-064, a Proprietary and Potential First-to-Market Regenerative Therapy for Persistent Smell LossCyrano Therapeutics announced positive topline results from its Phase 2 FLAVOR trial of CYR-064, an intranasal regenerative therapy for persistent post-viral smell loss (hyposmia), meeting its primary safety endpoint and key secondary efficacy endpoints in 151 patients across 14 U.S. clinical sites. The randomized, double-blind, placebo-controlled study showed no treatment-related serious adverse events and demonstrated durable improvements in smell function, with the company planning to advance into Phase 3 development in the second half of 2026. CYR-064 has the potential to become the first approved therapy for this condition, which affects more than 60 million people in the U.S., Europe, and Japan and currently has no effective pharmaceutical treatment.MorningstarKYORIN and Cyrano Therapeutics Enter into an Option Agreement for CYR-064 for the Treatment of Post-Viral Loss of Smell in JapanCyrano Therapeutics and KYORIN Pharmaceutical entered an option agreement for CYR-064, a treatment for post-viral loss of smell, with KYORIN licensing the drug in Japan. The deal includes upfront and milestone payments plus royalties, and CYR-064 is in a Phase 2 trial in the U.S. with data expected in H2 2025.Pulse 2.0Cyrano Therapeutics: $9 Million Raised To Help Combat Smell LossCyrano Therapeutics has secured $9 million in Series B financing to advance its treatment for post-viral smell loss, specifically for its intranasal therapy CYR-064. The company aims to conduct a Phase 2 clinical trial, named FLAVOR, at up to 15 sites in the US, targeting the increased number of patients experiencing long-term smell loss due to the COVID-19 pandemic. This financing supports the urgent need for a treatment as there is currently no FDA-approved therapy for smell loss from any cause.Venture Capital Access OnlineCyrano Therapeutics Secures $9.0 Million Series B Financing to Advance Clinical Development of CYR-064 for Treatment of Post-Viral Smell LossCyrano Therapeutics secured a $9.0 million Series B financing to advance the Phase 2 clinical trial of CYR-064, an intranasal spray for treating post-viral smell loss. The funding, led by DeepWork Capital and existing investors Lumira Ventures and Remiges Ventures, will support the FLAVOR trial across up to 15 sites in the US through data readout.Refresh MiamiCyrano Therapeutics raises $9M Series B round to combat loss of smellCyrano Therapeutics has raised $9 million in Series B financing to advance the development of CYR-064, a potential first treatment for post-viral smell loss. The funding, led by Florida Opportunity Fund and DeepWork Capital, will support a Phase 2 clinical trial conducted at up to 15 sites in the US. This investment aims to address the growing market of over 40 million patients in the US and Europe experiencing long-term smell loss following viral infections.PR NewswireCyrano Therapeutics Secures $9.0 Million Series B Financing to Advance Clinical Development of CYR-064 for Treatment of Post-Viral Smell LossCyrano Therapeutics secured $9.0 million in Series B financing to advance the clinical development of CYR-064, an intranasal therapy for post-viral smell loss. The funds will support the Phase 2 FLAVOR trial, which is currently enrolling 150 patients across up to 15 sites in the US. Co-lead investors DeepWork Capital, Lumira Ventures, and Remiges Ventures are backing the initiative to address a condition affecting millions globally with no existing FDA-approved treatments.BioSpaceCyrano Therapeutics Secures $9.0 Million Series B Financing to Advance Clinical Development of CYR-064 for Treatment of Post-Viral Smell LossCyrano Therapeutics secured $9.0 million in Series B financing to advance the clinical development of CYR-064, a potential first-ever treatment for post-viral smell loss. The funds will support the Phase 2 FLAVOR clinical trial, which is currently enrolling 150 patients across up to 15 sites in the US to assess the safety and effectiveness of the intranasal spray therapy. Co-lead investors DeepWork Capital, Lumira Ventures, and Remiges Ventures participated in the round to help fund the trial through data readout.